Abvc Biopharma, Inc. (ABVC) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$7.9M, or -$0.39 per diluted share. Operating activities generated -$3.0M of cash. At fiscal year end, Abvc Biopharma held $21.1M in total assets against $7.8M in total liabilities, including $681,480 of cash and equivalents.
Open the full interactive Abvc Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Abvc Biopharma Key Stats
| Share Price | $0.98 |
|---|---|
| Market Cap | $25.5M |
| 52-Week Range | $0.71 – $3.00 |
| Shares Outstanding | 26.1 million (basic, 2026 Q2) |
Abvc Biopharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $483,045 | $355,797 | $969,783 | $152,430 | $509,589 | — |
| Gross Profit | $464,329 | $350,711 | $683,368 | -$149,607 | $508,826 | — |
| Operating Income | -$8.5M | -$11.7M | -$15.1M | -$8.2M | -$4.7M | -$7.2M |
| Pre-Tax Income | -$10.8M | -$11.2M | -$15.5M | -$10.7M | -$5.4M | -$8.4M |
| Income Tax | -$220,352 | $825,024 | $797,778 | $256,006 | -$110,539 | $24,154 |
| Net Income | -$10.6M | -$12.0M | -$16.4M | -$10.5M | -$4.9M | -$7.9M |
| Diluted EPS | -$5.00 | -$5.10 | -$5.00 | -$2.43 | -$0.42 | -$0.39 |
Abvc Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $795,950 | — | — | — |
| Net Income | -$1.2M | -$3.6M | -$1.6M | -$736,934 |
| Diluted EPS | -$0.05 | -$0.18 | -$0.06 | -$0.03 |
Abvc Biopharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.3M | $5.8M | $85,265 | $60,155 | $248,382 | $681,480 |
| Current Assets | $6.2M | $9.6M | $3.0M | $1.7M | $2.2M | $2.5M |
| Total Assets | $11.6M | $13.7M | $9.9M | $14.5M | $7.5M | $21.1M |
| Current Liabilities | $4.8M | $3.7M | $5.8M | $5.9M | $6.6M | $6.2M |
| Total Long-Term Debt | $2.5M | — | — | $1.0M | — | — |
| Total Liabilities | $8.9M | $4.8M | $6.6M | $6.4M | $6.8M | $7.8M |
| Shareholders' Equity | $3.4M | $8.8M | $3.1M | $8.4M | $1.2M | $11.1M |
Abvc Biopharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$5.5M | -$7.6M | -$7.4M | -$4.2M | -$1.8M | -$3.0M |
| Cash From Investing | $751,303 | -$805,966 | -$1.7M | -$360,186 | — | -$1.2M |
| Cash From Financing | $9.6M | $10.0M | $4.0M | $3.9M | $2.0M | $4.6M |
| Free Cash Flow | — | -$7.6M | -$7.5M | -$4.3M | -$1.8M | — |
Figures from Abvc Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Abvc Biopharma financials page for every line item.
Abvc Biopharma Company Profile
| Ticker | ABVC |
|---|---|
| Exchange | Nasdaq, OTC |
| Industry | Pharmaceutical Preparations |
| Headquarters | Fremont, California |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001173313 |
Frequently Asked Questions
What is Abvc Biopharma's annual revenue history?
Abvc Biopharma's annual revenue by fiscal year: 2020: $483,045; 2021: $355,797; 2022: $969,783; 2023: $152,430; 2024: $509,589.
What was Abvc Biopharma's net income in fiscal 2025?
Abvc Biopharma reported net income of -$7.9M for fiscal 2025.
What was Abvc Biopharma's earnings per share (EPS) in fiscal 2025?
Abvc Biopharma's diluted EPS was -$0.39 for fiscal 2025 (adjusted for any later stock splits).
How many shares of Abvc Biopharma are outstanding?
Abvc Biopharma reported a weighted average of 26.1 million basic shares outstanding in 2026 Q2.
What is Abvc Biopharma's market cap?
Based on its latest closing price, Abvc Biopharma (ABVC) has a market capitalization of about $25.5M.
When does Abvc Biopharma's fiscal year end?
Abvc Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Abvc Biopharma headquartered?
Abvc Biopharma lists its business address in Fremont, California in its SEC filings.